PolarityTE Inc (PTE) Receives a Buy from Northland Securities


Northland Securities analyst Carl Byrnes maintained a Buy rating on PolarityTE Inc (PTE) today and set a price target of $50. The company’s shares opened today at $8.22, close to its 52-week low of $7.53.

Byrnes wrote:

“We remain highly confident in SkinTE’s commercial success for both burns, chronic wounds, and surgical reconstruction procedures.”

According to TipRanks.com, Byrnes is ranked 0 out of 5 stars with an average return of -6.3% and a 27.9% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adamas Pharmaceuticals, and Flexion Therapeutics.

Currently, the analyst consensus on PolarityTE Inc is a Strong Buy with an average price target of $39, which is a 374.5% upside from current levels. In a report issued on April 29, Cantor Fitzgerald also maintained a Buy rating on the stock with a $65 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $41.22 and a one-year low of $7.53. Currently, PolarityTE Inc has an average volume of 406.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PolarityTE, Inc. is a commercial-stage biotechnology and regenerative biomaterials company, which focuses on discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its products include SkinTE, OsteoTE and Real Time Assistant.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts